Target intelligence / Profile preview

Escherichia coli DNA (E. coli DNA)

Target
E. coli DNA
Molecular classification
Nucleic acid
01

Overview

Escherichia coli DNA is the circular, double-stranded genetic blueprint of the bacterium, typically comprising approximately 4.6 million base pairs that encode over 4,000 genes essential for cellular survival and virulence [3, 7]. In clinical pharmacology, this nucleic acid is a primary therapeutic target for agents that seek to arrest bacterial proliferation or induce rapid cell death by compromising genetic integrity [11, 21]. Certain drug classes, such as nitroimidazoles, are biochemically reduced within the bacterial cytoplasm to form reactive radicals that cause extensive DNA strand fragmentation and loss of helical structure [11]. Additionally, the DNA molecule serves as the site for the lethal action of topoisomerase poisons like fluoroquinolones, which trap enzymes such as DNA gyrase on the DNA backbone to create toxic, permanent double-strand breaks [1, 21]. Because E. coli is a frequent cause of infections ranging from uncomplicated urinary tract infections to life-threatening sepsis, targeting its DNA remains a cornerstone of antimicrobial strategy [2, 12, 17]. However, the therapeutic window of these agents is often constrained by potential toxicity to host mitochondrial DNA and the rapid emergence of resistance through mutations in the genes encoding DNA-processing enzymes [16, 21].

Other names
Escherichia coli genomic DNABacterial chromosomal DNAGenomic DNAEscherichia coli chromosome
02

Mechanism of action

Drugs targeting Escherichia coli DNA function by inducing direct physical damage, such as strand breakage and alkylation, or by stabilizing DNA-enzyme intermediates (e.g., topoisomerase-cleavage complexes) that result in irreversible double-strand breaks and inhibition of replication [1, 11, 21].

03

Biological functions

Genetic information storageDNA replicationTranscriptionDNA repairGenetic recombination
04

Disease associations

InfectionUrinary tract infectionSepsisMeningitisGastroenteritis
05

Safety considerations

Off-target genotoxicity to host cellsEmergence of multi-drug resistance (MDR)PhotosensitivityPeripheral neuropathyDisruption of the commensal gut microbiota (dysbiosis)
06

Interacting drugs

Metronidazole

7 more in the full profile.

07

Biomarkers

E. coli DNA detection (PCR)Bacterial load (CFU/mL)Minimum inhibitory concentration (MIC)

Beyond the preview

Go deeper on Escherichia coli DNA (E. coli DNA).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Escherichia coli DNA (E. coli DNA).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call